Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

Vanflyta (quizartinib)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Daiichi Sankyo

Drug class:

FLT3 inhibitor

Related drugs:

‹

›

FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	quizartinib Sensitive: A1 - Approval quizartinib Sensitive : A1	quizartinib Sensitive: A1 - Approval quizartinib Sensitive : A1
FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	quizartinib + RAIN-32 Sensitive: C2 – Inclusion Criteria quizartinib + RAIN-32 Sensitive : C2	quizartinib + RAIN-32 Sensitive: C2 – Inclusion Criteria quizartinib + RAIN-32 Sensitive : C2
FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	quizartinib Sensitive: C2 – Inclusion Criteria quizartinib Sensitive : C2	quizartinib Sensitive: C2 – Inclusion Criteria quizartinib Sensitive : C2
FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	quizartinib + RAIN-32 Sensitive: C2 – Inclusion Criteria quizartinib + RAIN-32 Sensitive : C2	quizartinib + RAIN-32 Sensitive: C2 – Inclusion Criteria quizartinib + RAIN-32 Sensitive : C2
FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	venetoclax + quizartinib Sensitive: C2 – Inclusion Criteria venetoclax + quizartinib Sensitive : C2	venetoclax + quizartinib Sensitive: C2 – Inclusion Criteria venetoclax + quizartinib Sensitive : C2
FLT3 mutation	Myelodysplastic Syndrome	FLT3 mutation	Myelodysplastic Syndrome	quizartinib Sensitive: C2 – Inclusion Criteria quizartinib Sensitive : C2	quizartinib Sensitive: C2 – Inclusion Criteria quizartinib Sensitive : C2
CBL mutation	Myelodysplastic Syndrome	CBL mutation	Myelodysplastic Syndrome	quizartinib Sensitive: C2 – Inclusion Criteria quizartinib Sensitive : C2	quizartinib Sensitive: C2 – Inclusion Criteria quizartinib Sensitive : C2
FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	gilteritinib + quizartinib + fingolimod Sensitive: C3 – Early Trials gilteritinib + quizartinib + fingolimod Sensitive : C3	gilteritinib + quizartinib + fingolimod Sensitive: C3 – Early Trials gilteritinib + quizartinib + fingolimod Sensitive : C3
FLT3 D835	Acute Myelogenous Leukemia	FLT3 D835	Acute Myelogenous Leukemia	quizartinib Sensitive: C3 – Early Trials quizartinib Sensitive : C3	quizartinib Sensitive: C3 – Early Trials quizartinib Sensitive : C3
DNMT3A mutation + FLT3-ITD mutation	Acute Myelogenous Leukemia	DNMT3A mutation + FLT3-ITD mutation	Acute Myelogenous Leukemia	quizartinib Sensitive: C3 – Early Trials quizartinib Sensitive : C3	quizartinib Sensitive: C3 – Early Trials quizartinib Sensitive : C3
DNMT3A mutation	Acute Myelogenous Leukemia	DNMT3A mutation	Acute Myelogenous Leukemia	quizartinib Sensitive: C3 – Early Trials quizartinib Sensitive : C3	quizartinib Sensitive: C3 – Early Trials quizartinib Sensitive : C3
NPM1 mutation	Acute Myelogenous Leukemia	NPM1 mutation	Acute Myelogenous Leukemia	quizartinib Sensitive: C3 – Early Trials quizartinib Sensitive : C3	quizartinib Sensitive: C3 – Early Trials quizartinib Sensitive : C3